Has Udit Chaddha, MD received payments from drug or device companies?

Yes. Drug and device makers reported $21,064 in general payments to Udit Chaddha, MD across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Udit Chaddha, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Udit Chaddha, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Udit Chaddha, MD

Pulmonary Disease · New York, NYNPI 1548524523

Payments from drug & device makers

$21,064in general payments, 2019–2025

Across 33 payments — averaging $638.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$15K
Intuitive Surgical$2K
Covidien LP$2K
Pinnacle Biologics, Inc$357
Johnson & Johnson$329
Steris Corporation$233
plus $296 from 4 others

What the payments were for

Speaking & faculty fees$2001%
Grants$15,00071%
Travel & lodging$3,81118%
Food & beverage$2,05310%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	4	$15,034
Intuitive Surgical	10	$2,431
Covidien LP	6	$2,385
Pinnacle Biologics, Inc	6	$357
Johnson & Johnson	2	$329
Steris Corporation	1	$233
Auris Health, Inc.	1	$122
Ambu Inc.	1	$73
Olympus America Inc.	1	$58
Olympus Corporation Of The Americas	1	$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,064 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York →

Medicare billing

Part B allowed, 2024

$117,785

Medicare patients

263

Services billed

819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	25	$17,199
Incruse ElliptaUmeclidinium Bromide	13	$4,306
Albuterol Sulfate HfaAlbuterol Sulfate	41	$1,061

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in New York

Linda RogersNew York$7.1M
Maria PadillaNew York$3.6M
Juan WisniveskyNew York$3M
Bushra MinaNew York$2.5M
Robert KanerNew York$2.3M
Doreen Addrizzo-HarrisNew York$1.9M
Emily DimangoNew York$1.4M
da ZhangNew York$1.3M
Claire KeatingNew York$1.2M
Charles PowellNew York$1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →